iMedicare, Mirixa partner on new integration
NEW YORK — Decision automation platform iMedicare and healthcare technology company Mirixa are working together to integrate patient counseling opportunities into the workflows of their partner pharmacies.
The integration of iMedicare’s plan comparison platform into Mirixa’s MirixaPro platform will enable pharmacies to take advantage of medication-related opportunities within their everyday workflow by prioritizing available clinical interventions for each specific patient.
“Mirixa is committed to innovation and technology which identifies and connects patients to trusted pharmacists,” Mirixa CEO Frank Harvey said. “We are excited to partner with a company like iMedicare to help pharmacies optimize patient engagement and take advantage of the opportunities to provide medication management services which improve patient health outcomes.”
The partnership comes on the heels of iMedicare’s implementation of machine learning and augmented reality to give member pharmacies an edge over their competition. The platform delivers easily digested information about local and national Medicare plans.
“Our goal is to provide pharmacies with the best opportunities at the best time, with the best ROI,” iMedicare CEO Flaviu Simihaian said. “This partnership with Mirixa enables thousands of pharmacies to improve health outcomes, while applying a sustainable business model for patient consultations.”
BD intros 6-mm pen needle for injection pens
FRANKLIN LAKES, N.J. — BD is bringing a new option for patients using pen injection devices. The BD Ultra-Fine micro pen needle 6 mm x 32 gauge is set for distribution in September, bringing a new needle length option to patients with diabetes who inject insulin.
The BD Ultra-Fine line also includes the 4 mm x 32 gauge, 5 mm x 31 gauge, 8 mm x 31 gauge and 12.7 mm x 29 gauge needles. The company said that the new needles were compatible with leading pen injection devices. With shorter needles in their pen injectors, patients with diabetes are less likely to accidentally inject their daily dose of insulin into a muscle, BD said.
“We added the BD Ultra-Fine micro pen needles to ensure BD has a comprehensive portfolio that provide options to patients and reinforces BD's commitment to providing the best solutions possible for people with specific preferences while managing their diabetes and striving for the best clinical outcomes," BD worldwide president of diabetes care and digital health Nabil Shabshab said. "This new needle will help ensure that people with diabetes who prefer a 6mm pen needle will be able to experience the quality and performance of BD Ultra-Fine pen needles.”
Mandatory controlled substance e-prescribing bill winds its way through Congress
A recently introduced bill from Reps. Katherine Clark, D-Mass., and Markwayne Mullin, R-Okla., has garnered interest from longtime proponents of e-prescribing in the retail pharmacy industry. The Every Prescription Conveyed Securely Act would require all controlled substances to be electronically prescribed.
The National Association of Chain Drug Stores was quick to praise the legislation. “[This] is an important step in combatting the abuse and diversion of prescription opioid medications,” NACDS president and CEO Steve Anderson wrote to the bill’s co-sponsors. “Electronic prescribing of controlled substances adds new dimensions of safety and security.”
In addition to its advocacy for e-prescribing, NACDS previously partnered with the National Community Pharmacy Association, helped create the health information network that merged with RxHub and now operates as Surescripts. In 2016, Surescripts said that it saw increased adoption of controlled substance e-prescribing, delivering 45.3 million scripts for controlled substances in 2016 — a 256% increase over the previous year.